Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates – Merck

Post author By EvidenceNotFear
Post date 27 January 2021

In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.

https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/

Tags COVID-19, Immunity, Merck, Vaccination

Info This site is a curated archive of articles with a link to the source. Keywords and topics covered in the publication can be found above. Click on the tag to view a listing of similar articles.
Links Are any links broken? The page may have been taken down. Visit archive.is or archive.org to view the archive snapshot.
Links Help fight censorship and preserve information on the internet. Archive this source and links on archive.is and archive.org. Save a local copy on your own hard drive.